SI2366405T1 - IL-17 antagonistic antibodies - Google Patents

IL-17 antagonistic antibodies

Info

Publication number
SI2366405T1
SI2366405T1 SI200531965T SI200531965T SI2366405T1 SI 2366405 T1 SI2366405 T1 SI 2366405T1 SI 200531965 T SI200531965 T SI 200531965T SI 200531965 T SI200531965 T SI 200531965T SI 2366405 T1 SI2366405 T1 SI 2366405T1
Authority
SI
Slovenia
Prior art keywords
antagonistic antibodies
antagonistic
antibodies
Prior art date
Application number
SI200531965T
Other languages
Slovenian (sl)
Inventor
Padova Franco E. Di
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Den Berg Wim Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2366405(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2366405T1 publication Critical patent/SI2366405T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SI200531965T 2004-08-05 2005-08-04 IL-17 antagonistic antibodies SI2366405T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
EP10174725.1A EP2366405B1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Publications (1)

Publication Number Publication Date
SI2366405T1 true SI2366405T1 (en) 2015-07-31

Family

ID=32982602

Family Applications (4)

Application Number Title Priority Date Filing Date
SI200531390T SI1776142T1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies
SI200532208T SI2902039T1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies
SI200531869T SI2364729T1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies
SI200531965T SI2366405T1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SI200531390T SI1776142T1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies
SI200532208T SI2902039T1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies
SI200531869T SI2364729T1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Country Status (39)

Country Link
US (8) US7807155B2 (en)
EP (5) EP2364729B3 (en)
JP (1) JP4682200B2 (en)
KR (2) KR100852523B1 (en)
CN (1) CN101001645B (en)
AR (1) AR050200A1 (en)
AT (1) ATE517924T1 (en)
AU (2) AU2005268857C1 (en)
BR (3) BR122017009404B1 (en)
CA (1) CA2573586C (en)
CY (6) CY1111963T1 (en)
DK (4) DK2902039T3 (en)
EC (1) ECSP077198A (en)
ES (4) ES2487533T7 (en)
FR (1) FR15C0048I2 (en)
GB (1) GB0417487D0 (en)
HK (3) HK1101277A1 (en)
HR (3) HRP20110758T4 (en)
HU (4) HUE025815T2 (en)
IL (1) IL180717A (en)
LT (3) LT2902039T (en)
LU (2) LU92768I2 (en)
MA (1) MA28982B1 (en)
MX (1) MX2007001338A (en)
MY (1) MY144925A (en)
NL (1) NL300749I2 (en)
NO (9) NO336279B1 (en)
NZ (1) NZ552658A (en)
PE (1) PE20060418A1 (en)
PL (4) PL2902039T3 (en)
PT (4) PT2902039T (en)
RU (2) RU2426741C3 (en)
SG (1) SG155186A1 (en)
SI (4) SI1776142T1 (en)
TN (1) TNSN07034A1 (en)
TR (1) TR201808057T4 (en)
TW (1) TWI359153B (en)
WO (1) WO2006013107A1 (en)
ZA (1) ZA200700242B (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101296706B (en) * 2005-09-01 2011-11-30 先灵公司 Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
SI1963368T1 (en) * 2005-12-13 2012-11-30 Lilly Co Eli Anti-il-17 antibodies
NZ616992A (en) 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
AR060017A1 (en) 2006-01-13 2008-05-21 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR DICKKOPF -1 ANTIBODIES
AU2007235199B8 (en) * 2006-01-31 2010-10-28 Novartis Ag IL-17 antagonistic antibodies for treating cancer
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
ES2373069T3 (en) 2006-08-11 2012-01-31 Schering Corporation ANTIBODIES FOR IL-17A.
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (en) 2007-02-12 2014-02-21 Merck Sharp & Dohme Use of il-23 antagonists for treatment of infection
CN101668531B (en) 2007-02-28 2014-05-07 默沙东公司 Combination therapy for treatment of immune disorders
US8282922B2 (en) 2007-05-29 2012-10-09 Novartis Ag Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody
WO2008156865A2 (en) * 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2009072802A2 (en) * 2007-12-03 2009-06-11 Amorepacific Corporation Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
AU2009204441B2 (en) * 2008-01-09 2015-03-05 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2279001B1 (en) * 2008-04-29 2015-09-30 Amgen Research (Munich) GmbH Inhibitors of gm-csf and il-17 for therapy
MX2010012090A (en) 2008-05-05 2011-04-11 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof.
AR072001A1 (en) 2008-06-03 2010-07-28 Abbott Lab IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CN102112494A (en) 2008-06-03 2011-06-29 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
ES2493042T3 (en) * 2008-09-29 2014-09-11 Roche Glycart Ag Antibodies against human IL-17 and their uses
JP5836807B2 (en) 2009-03-05 2015-12-24 アッヴィ・インコーポレイテッド IL-17 binding protein
CA2993053A1 (en) * 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
EP2473524A4 (en) 2009-09-01 2013-05-22 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
EP2488658A4 (en) 2009-10-15 2013-06-19 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
KR101836217B1 (en) 2009-10-30 2018-03-08 얀센 바이오테크 인코포레이티드 Il-17a antagonists
BR112012029588A2 (en) 2010-05-20 2017-07-25 Ablynx Nv her3-related biological materials.
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
EP2601217B1 (en) * 2010-08-05 2017-06-14 AnaptysBio, Inc. Antibodies directed against il-17
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20130139884A (en) 2010-08-26 2013-12-23 애브비 인코포레이티드 Dual variable domain immunoglobulins and uses thereof
ES2862955T3 (en) 2010-10-01 2021-10-08 Modernatx Inc Manipulated nucleic acids and methods of using them
KR20150018595A (en) * 2010-10-08 2015-02-23 노파르티스 아게 Methods of treating psoriasis using il-17 antagonists
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
DE20187001T1 (en) 2010-11-05 2021-04-01 Novartis Ag METHOD OF TREATMENT OF PSORIASUS ARTHRITIS WITH IL-17 ANTAGONISTS
TW201307845A (en) 2010-12-13 2013-02-16 Novartis Ag Predictive methods and methods of treating arthritis using IL-17 antagonists
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
JP5947041B2 (en) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 Safe IL-17 production inhibitor
US20140004540A1 (en) * 2011-01-13 2014-01-02 Universite Paris Descartes Methods and kits for predicting the risk of having a cardiovascular event in a subject
AU2012206431B2 (en) 2011-01-14 2015-04-30 UCB Biopharma SRL Antibody molecules which bind IL-17A and IL-17F
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
CN103547589A (en) * 2011-03-29 2014-01-29 葛兰素史密斯克莱有限责任公司 Buffer system for protein purification
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013052523A1 (en) 2011-10-03 2013-04-11 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RU2014125071A (en) 2011-11-21 2015-12-27 Новартис Аг METHODS FOR TREATING PSORIATIC ARTHRITIS (PSA) USING IL-17 ANTAGONISTS AND PSA RESPONSE ALLELEES OR NO PSA RESPONSE
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CN104114572A (en) 2011-12-16 2014-10-22 现代治疗公司 Modified nucleoside, nucleotide, and nucleic acid compositions
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CN104159920A (en) 2011-12-30 2014-11-19 艾伯维公司 Dual specific binding proteins directed against il-13 and/or il-17
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
EP2833920A2 (en) 2012-04-02 2015-02-11 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
KR101674784B1 (en) 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 Bispecific antibodies against human tweak and human il17 and uses thereof
RU2014146594A (en) 2012-04-20 2016-06-10 Новартис Аг METHODS FOR TREATING ANKLOSING SPONDILITIS USING IL-17 ANTAGONISTS
SI2852615T1 (en) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
AR093297A1 (en) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
KR20180008921A (en) 2012-11-01 2018-01-24 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
CA2897682C (en) 2013-02-08 2023-03-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
CN105324396A (en) 2013-03-15 2016-02-10 艾伯维公司 Dual specific binding proteins directed against il-1 beta and il-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
EP3889178A1 (en) 2013-08-30 2021-10-06 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN104936981B (en) * 2013-11-18 2018-02-27 上海恒瑞医药有限公司 IL 17A conjugates and application thereof
CN105916883B (en) * 2014-01-28 2019-12-03 北京韩美药品有限公司 Bifunctional fusion proteins and its preparation method and application
TWI713453B (en) 2014-06-23 2020-12-21 美商健生生物科技公司 Interferon alpha and omega antibody antagonists
CA2960754A1 (en) 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
RU2609627C2 (en) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
MX2017004810A (en) 2014-10-14 2017-10-16 Novartis Ag Antibody molecules to pd-l1 and uses thereof.
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103172A1 (en) * 2014-12-22 2017-04-19 Novartis Ag SELECTIVE REDUCTION OF CYSTEINE WASTE IN ANTIBODIES IL-17
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
CA2972683A1 (en) 2015-01-12 2016-07-21 Affibody Ab Il-17a-binding polypeptides
JP2018506275A (en) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド Gene expression markers and treatment of multiple sclerosis
CN105315371B (en) 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 Anti-human IL-17 monoclonal antibodies
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
AU2016294332A1 (en) 2015-07-16 2017-11-30 Eli Lilly And Company Treatment of pruritus
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (en) 2015-07-29 2021-06-28 Immutep Sas COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
CN108367074A (en) 2015-10-19 2018-08-03 诺华股份有限公司 Use interleukin-17（IL-17）The method of antagonist for treating radiology feminine gender mesinae joint of vertebral column inflammation
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
KR20240017421A (en) 2016-03-10 2024-02-07 비엘라 바이오, 인크. Ilt7 binding molecules and methods of using the same
CN116284392A (en) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 Activin type 2 receptor binding proteins and uses thereof
RU2680011C2 (en) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Trispecific il-17a, il-17f and other proinflammatory molecules antibodies
FR3051673B1 (en) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris INHIBITORS OF THE INTERLEUKIN 17 PATHWAY FOR THE TREATMENT OF CHRONIC DISEASES DUE TO HPV
CN107488227A (en) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 Anti-human IL-17 A monoclonal antibodies, its preparation method and application
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
CN109476733A (en) 2016-07-19 2019-03-15 诺华股份有限公司 The method for newly sending out psoriasis in plaques using IL-17 antagonist for treating
AU2017328310B2 (en) 2016-09-14 2020-10-15 Beijing Hanmi Pharm. Co., Ltd. Antibody specifically binding to IL-17A and functional fragment thereof
JP2019505516A (en) 2016-11-28 2019-02-28 ノバルティス アーゲー Method of treating acne using an interleukin-17 (IL-17) antagonist
MY197534A (en) 2017-02-10 2023-06-21 Genentech Inc Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (en) 2017-05-05 2018-12-16 瑞士商諾華公司 Methods of selectively treating asthma using il-17 antagonists
CN108359011B (en) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 Target the antibody, preparation method and application of interleukin-17 A
JP2021501752A (en) 2017-11-02 2021-01-21 ノバルティス アーゲー How to treat tendon disorders with interleukin-17 (IL-17) antagonists
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
TW201925782A (en) 2017-11-30 2019-07-01 瑞士商諾華公司 BCMA-targeting chimeric antigen receptor, and uses thereof
JP2021519589A (en) * 2018-03-29 2021-08-12 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ Treatment of autoimmune and inflammatory disorders with antibodies that bind to interleukin 17A (IL-17A)
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
KR20210122243A (en) 2019-01-31 2021-10-08 누맙 세러퓨틱스 아게 Multispecific antibodies having specificity for LNF and L-17A, antibodies targeting LLA-17A, and methods of using the same
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
UA128098C2 (en) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Therapeutic antibody formulation
CN110179746A (en) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 A kind of stable Su Jin monoclonal antibody injection and preparation method thereof
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (en) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 Feed supplement culture medium for CHO cell culture and preparation method and application thereof
BR112022001492A2 (en) 2019-07-26 2022-03-22 Sinocelltech Ltd Humanized anti-il17a antibody and use thereof
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
JP2022549200A (en) 2019-09-20 2022-11-24 ノバルティス アーゲー Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
CA3156167A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Compositions and methods for an il-17 target engagement assay with large molecule modulators
CN114728060A (en) 2019-11-19 2022-07-08 诺华股份有限公司 Methods of treating lupus nephritis using interleukin-17 (IL-17) antagonists
US20220403018A1 (en) 2019-12-06 2022-12-22 Novartis Ag Methods of treating lichen planus using interleukin (il-17) antagonists
CN114805577B (en) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 Antibody for IL-17RA protein, preparation method and application thereof
AU2021296436A1 (en) 2020-06-23 2023-02-02 Novartis Ag Methods of treating Thyroid Eye Disease and Graves' Orbitopahy using Interleukin-17 (IL-17) antagonists
UY39484A (en) 2020-11-02 2022-06-30 Novartis Ag INTERLEUKIN-17 INHIBITORS
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
US20240043523A1 (en) 2020-12-02 2024-02-08 Fresenius Kabi Deutschland Gmbh Methods of selectively reducing antibodies
IL303951A (en) 2020-12-22 2023-08-01 Novartis Ag Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
WO2023209519A1 (en) 2022-04-25 2023-11-02 Novartis Ag Crystalline forms of an il-17 inhibitor
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
PT817847E (en) 1995-03-23 2005-02-28 Immunex Corp IL-17 RECEPTOR
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
PT839196E (en) * 1995-07-19 2005-09-30 Inst Genetics Llc CTLA-8 HUMAN AND CTLA-8 RELATED PROTEIN UTILIZATIONS
CA2235951C (en) 1995-10-27 2003-04-01 Schering Corporation Novel uses of mammalian ctla-8 and related reagents
EP0959897B1 (en) 1996-11-27 2009-04-22 Immunex Corporation Method of regulating nitric oxide production
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
WO1999014240A1 (en) 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
CA2309604C (en) 1997-11-10 2010-01-12 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
AU2004799A (en) 1997-12-19 1999-07-12 Millennium Biotherapeutics, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
EP1045905A2 (en) 1998-01-09 2000-10-25 Immunex Corporation Il-17rh dna and polypeptides
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
AU3291099A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Genetic vaccine vector engineering
EP2333069A3 (en) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
EP1114156B1 (en) 1998-09-17 2007-11-14 ZymoGenetics, Inc. Mammalian transforming growth factor beta - 9 (ztgfss9)
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (en) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd Therapeutic agent for and diagnosis of chronic rheumatism and
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DE29820466U1 (en) 1998-11-16 1999-04-08 Reutter Werner Prof Dr Med Recombinant glycoproteins and medicinal products containing them
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AU3207000A (en) 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
KR20010089764A (en) 1999-01-11 2001-10-08 둘락 노먼 씨. Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
PL200919B1 (en) 1999-02-12 2009-02-27 Lexigen Pharm Corp Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (en) * 1999-09-09 2001-03-30 Nec Corp Portable telephone system with camera
CA2407910C (en) 2000-06-16 2013-03-12 Steven M. Ruben Antibodies that immunospecifically bind to blys
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
DE60125563T2 (en) 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis METHOD FOR USE OF A HUMAN IL-17 RELATED POLYPEPTIDE FOR THE TREATMENT OF DISEASES
MXPA03003407A (en) * 2000-10-18 2004-05-04 Immunex Corp Methods for treating rheumatoid arthritis using il-17 antagonists.
WO2002102411A2 (en) 2001-01-25 2002-12-27 Zymogenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
EP1456347A4 (en) 2001-11-16 2006-08-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
JP2006508056A (en) 2002-08-28 2006-03-09 イミュネックス・コーポレーション Compositions and methods for treating cardiovascular disease
JP4999158B2 (en) * 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド Human monoclonal antibody against infection protective antigen of Bacillus anthracis
PL1983000T3 (en) 2003-11-21 2016-02-29 Ucb Biopharma Sprl Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
CA2565566A1 (en) * 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
CN101296706B (en) * 2005-09-01 2011-11-30 先灵公司 Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
BRPI0513078C1 (en) 2021-05-25
TWI359153B (en) 2012-03-01
RU2426741C2 (en) 2011-08-20
ECSP077198A (en) 2007-02-28
PL1776142T6 (en) 2016-06-30
US20090280131A1 (en) 2009-11-12
DK2366405T3 (en) 2015-05-11
HUS1500037I1 (en) 2017-10-30
EP2366405A2 (en) 2011-09-21
CY1116256T1 (en) 2017-02-08
FR15C0048I2 (en) 2015-11-20
CY1111963T1 (en) 2015-11-04
HRP20150480T1 (en) 2015-07-17
EP1776142B3 (en) 2015-06-24
ATE517924T1 (en) 2011-08-15
HK1101277A1 (en) 2007-10-12
CA2573586A1 (en) 2006-02-09
LU92768I2 (en) 2015-11-03
HRP20110758T4 (en) 2015-07-31
LT2902039T (en) 2018-06-25
KR100852523B1 (en) 2008-08-14
ZA200700242B (en) 2008-08-27
US9765140B2 (en) 2017-09-19
HRP20181069T1 (en) 2018-09-07
PL1776142T3 (en) 2011-12-30
GB0417487D0 (en) 2004-09-08
EP2366405A3 (en) 2012-01-18
FR15C0048I1 (en) 2015-08-28
CY2018027I1 (en) 2020-05-29
PT1776142E (en) 2011-10-06
LUC00088I2 (en) 2018-12-17
HUE038187T2 (en) 2018-10-29
NO20151787L (en) 2006-02-06
TW200617025A (en) 2006-06-01
NO2016017I1 (en) 2016-08-23
NO2022026I1 (en) 2022-06-24
RU2007108067A (en) 2008-09-10
PL2902039T3 (en) 2018-09-28
AU2005268857C1 (en) 2012-01-19
MY144925A (en) 2011-11-30
CY2015030I1 (en) 2015-11-04
EP2364729A2 (en) 2011-09-14
DK1776142T3 (en) 2011-10-31
SI1776142T1 (en) 2011-11-30
AU2010201689B2 (en) 2011-09-29
EP2366405B1 (en) 2015-02-25
LTPA2018515I1 (en) 2018-10-25
DK1776142T6 (en) 2015-07-06
NO337286B1 (en) 2016-02-29
CY1120723T1 (en) 2019-12-11
ES2536228T3 (en) 2015-05-21
US20120107325A1 (en) 2012-05-03
AU2005268857A1 (en) 2006-02-09
NO20150064L (en) 2007-03-30
RU2426741C3 (en) 2017-11-15
EP2364729B3 (en) 2015-06-24
CN101001645A (en) 2007-07-18
HRP20110758T1 (en) 2011-11-30
US7807155B2 (en) 2010-10-05
BR122018075556B1 (en) 2022-10-18
US20100215666A1 (en) 2010-08-26
CY2015030I2 (en) 2017-11-14
EP1776142B9 (en) 2016-09-07
AU2010201689A1 (en) 2010-05-20
DK2364729T3 (en) 2014-07-21
ES2367440T7 (en) 2015-07-14
US8119131B2 (en) 2012-02-21
EP3409288A1 (en) 2018-12-05
HK1256639A1 (en) 2019-09-27
RU2011113153A (en) 2012-10-20
US10344084B2 (en) 2019-07-09
DK2902039T3 (en) 2018-07-16
PT2364729E (en) 2014-09-01
EP2364729B1 (en) 2014-05-14
CA2573586C (en) 2013-06-25
BRPI0513078B1 (en) 2019-02-19
HUS1800040I1 (en) 2018-11-28
PT2902039T (en) 2018-07-17
LTC1776142I2 (en) 2022-07-11
NO2015023I1 (en) 2015-11-02
AU2005268857B8 (en) 2010-05-27
KR20070036166A (en) 2007-04-02
ES2487533T7 (en) 2015-07-14
NZ552658A (en) 2009-11-27
US20230235038A1 (en) 2023-07-27
IL180717A0 (en) 2007-06-03
EP1776142B1 (en) 2011-07-27
NO2018007I1 (en) 2018-02-14
CN101001645B (en) 2012-09-05
TNSN07034A1 (en) 2008-06-02
ES2367440T3 (en) 2011-11-03
NO20070985L (en) 2007-03-30
EP1776142A1 (en) 2007-04-25
EP2902039B1 (en) 2018-04-11
NO20171697A1 (en) 2007-03-30
PT2366405E (en) 2015-06-30
AR050200A1 (en) 2006-10-04
HUE025815T2 (en) 2016-04-28
KR20080029018A (en) 2008-04-02
ES2487533T3 (en) 2014-08-21
BR122017009404B1 (en) 2022-02-22
NO336279B1 (en) 2015-07-06
CY1115444T1 (en) 2017-01-04
PL1776142T4 (en) 2018-04-30
ES2677245T3 (en) 2018-07-31
NL300749I2 (en) 2017-11-02
NO20150065L (en) 2007-03-30
IL180717A (en) 2012-07-31
BRPI0513078A (en) 2008-04-22
MA28982B1 (en) 2007-11-01
WO2006013107A1 (en) 2006-02-09
PL2364729T6 (en) 2016-06-30
LTPA2015029I1 (en) 2022-07-11
PL2366405T3 (en) 2015-08-31
NO341384B1 (en) 2017-10-30
BRPI0513078B8 (en) 2019-08-27
SI2364729T1 (en) 2014-08-29
US20150152178A1 (en) 2015-06-04
PE20060418A1 (en) 2006-06-15
TR201808057T4 (en) 2018-06-21
US20170355762A1 (en) 2017-12-14
SI2902039T1 (en) 2018-07-31
PL2364729T3 (en) 2014-10-31
SG155186A1 (en) 2009-09-30
US8617552B2 (en) 2013-12-31
CY2018027I2 (en) 2020-05-29
ES2367440T9 (en) 2021-04-28
US20140079719A1 (en) 2014-03-20
MX2007001338A (en) 2008-03-11
DK2364729T6 (en) 2015-07-06
US20190270804A1 (en) 2019-09-05
NO337129B1 (en) 2016-01-25
AU2005268857B2 (en) 2010-01-28
HK1207559A1 (en) 2016-02-05
NO2015023I2 (en) 2015-10-26
JP4682200B2 (en) 2011-05-11
JP2008507988A (en) 2008-03-21
EP2364729A3 (en) 2012-01-18
EP2902039A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
HK1256639A1 (en) Il-17 antagonistic antibodies
IL237756A0 (en) Antibody formulations
IL181575A0 (en) Anti-ox40l antibodies
IL228032A0 (en) Antibodies
HK1153209A1 (en) Antagonistic human light-specific human monoclonal antibodies
GB0420466D0 (en) Anti-glucan antibodies
ZA200701952B (en) Anti-OX40L antibodies
EP1780221A4 (en) Anti-synoviolin antibody
GB0418415D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies